title: The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.
abstract: The αGal HyperAcute(®) Technology exploits a robust zoonotic blockade to enhance potency of antiviral vaccines. Naturally acquired immunity against the common αGal epitope [galactose-alpha(1,3)-galactose-beta(1,4)N-acetylglucosamine-R (Gal-α(1,3)-Gal-β(1,4)-GlcNAc-R)] is facilitated by the loss of a key enzyme in the epitope's biosynthetic pathway. As human cells are devoid of this epitope, chronic stimulus from gut flora leads to high levels of circulating anti-αGal antibodies and the development of a robust immune pathway. As the αGal epitope is immediately recognized as foreign, the naturally acquired αGal immune pathway in humans serves as a strong barrier to zoonotic infection. The αGal HyperAcute(®) Technology takes advantage of this natural process to facilitate the rapid presentation of modified antigens to antigen-presenting cells, leading to a strong immune response. The evolutionary immunity to αGal ensures that the presence of αGal epitopes on antigens will lead to a robust immune response involving cross-activation of T(H)1 immunity, characterized by cytokine secretion and increased phagocytic activity, and T(H)2 immunity characterized by high antibody titres. αGal epitopes can be applied to antiviral vaccines by biological, enzymatic or chemical means. Several detection methods that directly and indirectly verify αGal addition are discussed. Enhanced immunogenicity (humoral and cellular) of αGal-modified vaccines is shown for several antiviral vaccine candidates. αGal modification of antiviral vaccine components leads to enhanced immunogenicity. The existing body of literature describing the utility of αGal epitopes as a safe and robust immunostimulatory and -modulatory agent in humans supports the basis for applying the αGal HyperAcute(®) Technology to the improvement of antiviral vaccines, both new and currently approved.
authors.affiliation: BioProtection Systems Corporation, Ames, IA, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Mandell
authors.forename: R
authors.initials: R
authors.lastname: Flick
authors.forename: W R
authors.initials: WR
authors.lastname: Staplin
authors.forename: L D
authors.initials: LD
authors.lastname: Kaniewski
authors.forename: A K
authors.initials: AK
authors.lastname: Carzoli
authors.forename: R P
authors.initials: RP
authors.lastname: Manuszak
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: G R
authors.initials: GR
authors.lastname: Rossi
authors.forename: N N
authors.initials: NN
authors.lastname: Vahanian
authors.forename: C J
authors.initials: CJ
authors.lastname: Link
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D002478:Cells, Cultured; D000939:Epitopes / Q000378:metabolism; D005700:Galactosyltransferases / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*; D015047:Zoonoses
chemical_list: D000276:Adjuvants, Immunologic; D000939:Epitopes; D014765:Viral Vaccines; D005700:Galactosyltransferases; C047006:N-acetyllactosaminide alpha-1,3-galactosyltransferase